Prasit Chai Calls Out Potential Monopoly in Cannabis Reclassification Efforts

By Thailand THC

thailandTHC > News > Prasit Chai Calls Out Potential Monopoly in Cannabis Reclassification Efforts

Last updated on June 25th, 2024 at 10:09 am

  • Driving The News: Prasit Chai Noonwal, leader of the Thai Cannabis Network, questions the motives behind reclassifying cannabis as a narcotic, alleging capitalist influence.
  • Why It Matters: The reclassification could lead to monopolization of cannabis cultivation and hinder the progress made in cannabis legalization.
  • The Big Picture: The debate emphasizes the need for transparent policies that prioritize public health and economic benefits over corporate interests.

BANGKOK, THAILAND – On June 14, Prasit Chai Noonwal, a prominent leader of the Thai Cannabis Network, expressed strong skepticism about the motives behind the government’s proposal to reclassify cannabis as a narcotic. In a Facebook post, Prasit Chai suggested that the push for reclassification is driven by corporate interests rather than genuine concern for youth welfare, as claimed by proponents of the move.

Prasit Chai highlighted that the reclassification could lead to a monopolization of cannabis cultivation, where only a few large corporations would benefit. “It’s perplexing to see how this issue, initially about resolving conflicts with the Ministry of Public Health, has now seen corporate players taking charge and advocating for cannabis to be reclassified as a narcotic. This raises questions about their true intentions,” he stated.

He argued that the alleged goal of protecting youth is a facade, masking the real intention of controlling the lucrative cannabis market. “They are locking down cannabis while letting methamphetamines run rampant. Are they genuinely concerned about youth, or are they aiming for a monopoly?” he questioned.

Prasit Chai called for a transparent and balanced approach to cannabis regulation, one that ensures public health and economic benefits are prioritized over corporate gains. He urged stakeholders to consider the broader implications of reclassification on both patients and the cannabis industry.

Contributing Sources: Naewna